Niklas Beschorner

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy.

Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy.

Journal: bioRxiv : the preprint server for biology
Published: May 13, 2026

Development of an investigational medicinal stem cell gene therapy product to attempt curing human immunodeficiency virus infection.

Development of an investigational medicinal stem cell gene therapy product to attempt curing human immunodeficiency virus infection.

Journal: Scientific reports
Published: April 20, 2026

Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1.

Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1.

Journal: PloS one
Published: August 29, 2023

Precise excision of HTLV-1 provirus with a designer-recombinase.

Precise excision of HTLV-1 provirus with a designer-recombinase.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 28, 2022

Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors.

Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors.

Journal: PloS one
Published: July 29, 2021

Improving Lentiviral Transduction of CD34+ Hematopoietic Stem and Progenitor Cells.

Improving Lentiviral Transduction of CD34+ Hematopoietic Stem and Progenitor Cells.

Journal: Human gene therapy methods
Published: April 11, 2018

Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.

Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.

Journal: Nature biotechnology
Published: April 30, 2015

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

Journal: Scientific reports
Published: January 11, 2015

d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers.

d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers.

Journal: RNA biology
Published: December 14, 2012
Showing 1-9 of 9

Last Updated: 09/26/2026